(Q45751632)

15 December 2017

title

An economic analysis of different strategies of immunization against hepatitis A virus in developed countries (English)

1 reference

15 December 2017

0 references

1 reference

1 reference

Das A

1

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 February 1999

1 reference

15 December 2017

published in

Hepatology

1 reference

15 December 2017

volume

29

1 reference

15 December 2017

issue

2

1 reference

15 December 2017

page(s)

548-552

1 reference

15 December 2017

Antibody against hepatitis A in seven European countries. I. Comparison of prevalence data in different age groups

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Epidemiological patterns of hepatitis A in different parts of the world

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Clinical experience with an inactivated hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Hepatitis B immunization in a low-incidence province of Canada: comparing alternative strategies

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

An economic evaluation of universal vaccination against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

The Markov process in medical prognosis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Health problems after travel to developing countries

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

The cost of a food-borne outbreak of hepatitis A in Denver, Colo

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Will hepatitis A become a vaccine-preventable disease?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Cost-effectiveness analysis of vaccination against hepatitis A in travellers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Five‐Hundred Life‐Saving Interventions and Their Cost‐Effectiveness

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Relapsing hepatitis A. Review of 14 cases and literature survey

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Immunogenicity of two versus three injections of inactivated hepatitis A vaccine in adults.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Perspectives on the control of hepatitis A by vaccination

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Monitoring childhood immunizations: a Canadian approach

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510290225

7 January 2021

Identifiers

DOI

10.1002/HEP.510290225

1 reference

15 December 2017

1 reference

15 December 2017